H1B Report
Side-by-side comparison

Deloitte Consulting LLP vs Molecular Epidemiology, Inc.

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
Deloitte Consulting LLP
PARank #4FEIN 06-1454513
Entity B
Molecular Epidemiology, Inc.
WARank #FEIN 91-1759869

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricDeloitte Consulting LLPMolecular Epidemiology, Inc.
Total filings80,81378
Certified %98.23%57.69%
Denied %1.09%2.56%
Withdrawn %0.61%5.13%
Cert-withdrawn %0.07%34.62%
Rank#4
Active yearsFY2010–FY2026FY2010–FY2026
Worksite statePAWA

Outcomes — Deloitte Consulting LLP

DOL case-status mix.

Outcome breakdown: Certified 98.2%, Cert-withdrawn 0.1%, Withdrawn 0.6%, Denied 1.1%
Outcome breakdown
OutcomeShare
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%
Certified98.2%
Cert-withdrawn0.1%
Withdrawn0.6%
Denied1.1%

Outcomes — Molecular Epidemiology, Inc.

DOL case-status mix.

Outcome breakdown: Certified 57.7%, Cert-withdrawn 34.6%, Withdrawn 5.1%, Denied 2.6%
Outcome breakdown
OutcomeShare
Certified57.7%
Cert-withdrawn34.6%
Withdrawn5.1%
Denied2.6%
Certified57.7%
Cert-withdrawn34.6%
Withdrawn5.1%
Denied2.6%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

Deloitte Consulting LLP
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20102,375
FY20113,610
FY20124,716
FY20136,082
FY20147,007
FY20157,572
FY20167,629
FY20177,147
FY201816,089
FY20197,754
FY202052
FY202135
FY202211
FY20231,134
FY20242,702
FY20254,286
FY20262,612
Molecular Epidemiology, Inc.
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201019
FY20111
FY20126
FY20134
FY20144
FY20158
FY20165
FY20176
FY20186
FY20195
FY20200
FY20210
FY20220
FY20230
FY20244
FY20255
FY20265

Top 5 occupations — Deloitte Consulting LLP

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.